CYIGinactive

SPRING PHARMACEUTICAL GROUP, INC.

Healthcare·Oncology·Commercial
OncologyRare DiseaseNeurologyImmunologyCardiovascularInfectious DiseaseMetabolicRespiratoryHematologyReproductivePsychiatry

SPRING PHARMACEUTICAL GROUP, INC. (CYIG): 26 pipeline candidates · ~39 mo cash runway · 33 clinical trials. Updated within the last hour.

10.0/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway10.0

39.2 months

Financial Health10.0

0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

26 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for SPRING PHARMACEUTICAL GROUP, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$36.0M

Quarterly Burn

$2.9M

Runway

39.2 mo

Revenue

$19.5M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Sep 2029
Today~43 mo out
Catalyst within runway

Pipeline (26 candidates)

DrugPhase
anlotinibPhase 2
anlotinibPhase 2
apixabanApproved
ginkgo herbal teaApproved
glyceryl bromide/formoterol inhalation aerosolPhase 2
hsk46575Phase 1
huoliyuanApproved
hydroxycarbamidePhase 2
js1-1-01 high-dose groupPhase 2/Phase 3
js1-1-01 low-dose groupPhase 2/Phase 3

Showing 10 of 26 candidates. Sign up for full pipeline.

33 clinical trials·2 FDA decisions·CEO: Tinghe Yan

Frequently asked questions

How many drug candidates are in SPRING PHARMACEUTICAL GROUP, INC.'s pipeline?

SPRING PHARMACEUTICAL GROUP, INC. (CYIG) has 26 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is SPRING PHARMACEUTICAL GROUP, INC.'s lead drug candidate?

SPRING PHARMACEUTICAL GROUP, INC.'s most advanced tracked candidate is anlotinib (Phase 2) for Advanced Lung Cancer.

What is SPRING PHARMACEUTICAL GROUP, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, SPRING PHARMACEUTICAL GROUP, INC. has approximately 39.2 months of cash runway.

Who is the CEO of SPRING PHARMACEUTICAL GROUP, INC.?

Tinghe Yan is the chief executive officer of SPRING PHARMACEUTICAL GROUP, INC. (CYIG).

Get the full picture on SPRING PHARMACEUTICAL GROUP, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar